# CVS Health Corp. (CVS) – NYSE

**Analyst Rating:** HOLD (Strong near-term results offset by residual benefit‐pressures; recovery in 2025 expected to more than offset recent weakness)  
**Target Price:** $72 (USD, 12-month) – implies ~14× FY2025 EPS, near peer median; see Valuation below.  
**Report Date:** 2025-05-06  
**Last Close:** $69.84 (5/6/25) ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-health-raises-annual-profit-forecast-as-turnaround-gathers-steam-4015961#:~:text=CVS%20shares%20jumped%205,75%20to%20%246%20previously)); **52-Week Range:** $43.56–$72.51 ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/stock-price-history#:~:text=2022.%20,below%20the%20current%20share%20price)); **Market Cap:** ~$76.8 B ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/stock-price-history#:~:text=Sector%20%20,Its%20offerings%20include)); **Dividend (TTM):** ~$2.66 (67¢/Q) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=The%20quarterly%20cash%20dividend%20declared,Company%E2%80%99s%20earnings%2C%20capital%20requirements%2C%20financial)) (~3.8% yield at last close); **Shares O/S:** 1,265 M ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=As%20of%20April%C2%A023%2C%202025%2C%20the,common%20stock%20issued%20and%20outstanding)).  
**Key Valuation Multiples:** FY25 P/E ~16× (consensus GAAP EPS ~4.4), FY24 P/E ~19×; P/S ~0.2 (Market Cap/2024 revenue ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/stock-price-history#:~:text=Sector%20%20,Its%20offerings%20include))), P/B ~1.0 (Price/Book equity ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Total%20shareholders%E2%80%99%20equity%20%20,253%2C215))).  
**Sector:** Healthcare (Integrated Payor/Provider) – **Stance:** Market Weight.  
**Financial Strength:** Medium (substantial long-term debt ~$60B vs. equity ~$77 B; strong cash flow and liquidity ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Cash%20and%20cash%20equivalents%20,28%2C934)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Total%20shareholders%E2%80%99%20equity%20%20,253%2C215))). 

• **Q1’25 Results:** Revenues up 7.0% YOY to $94.6B; GAAP EPS $1.41 vs. $0.88 in Q1’24, adj. EPS $2.25 vs. $1.31 ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=First%20Quarter%20Financial%20Highlights)) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=,%24%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%200.94)). Growth was broad-based: insurance premiums (Aetna) +7–8%, pharmacy sales +7–8%, services (care management) flat. HCB profit jumped on improved Medicare Advantage (MA) star ratings (medical loss ratio fell to 87.3% from 90.4% ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=%2A%20Total%20revenues%20increased%208.0,increases%20were%20partially%20offset%20by))) and favorable prior-year development; pharmacy segment also grew via volume and specialty drugs (e.g. GLP-1s). Partly offsetting these gains, CVS booked a $448 M “premium deficiency” reserve in the ACA exchange business ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=,improved%20underlying%20performance%20in%20Medicare)) and took a $387 M litigation charge (Omnicare jury verdict) in Q1. Operating income rose 48.6% YOY ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=%2A%20Total%20revenues%20increased%207.0,three%20months%20ended%20March%2031)) (vs. only 7% rev growth), reflecting strong adjusted income and absence of prior-year opioid-related charges. Interest expense increased modestly.  

• **Guidance:** After Q1, CVS lowered FY2025 GAAP EPS guidance to $4.23–$4.43 (from $4.58–$4.83) but raised adjusted EPS to $6.00–$6.20 (from $5.75–$6.00) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=2025%20Full)). OCF guidance was lifted to ~$7.0B. Management attributed revisions to “strong performance across each business” but remains cautious on ongoing cost inflation and macro headwinds ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=flow%20from%20operations%20guidance%20to,the%20potential%20for%20macro%20headwinds)). CVS reiterated share-count and dividend targets, with no cut to its quarterly $0.665 payout ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=The%20quarterly%20cash%20dividend%20declared,Company%E2%80%99s%20earnings%2C%20capital%20requirements%2C%20financial)). 

• **Operations Update:** CVS confirmed it will exit the ACA individual market by 2026 ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-health-raises-annual-profit-forecast-as-turnaround-gathers-steam-4015961#:~:text=%28Reuters%29%20,series%20of%20challenges%20last%20year)), after sustained losses. It is also testing smaller “5,000-sq.ft.” store formats (focusing on pharmacy & essentials) and plans to close ~270 underperforming stores nationwide in 2025 ([www.axios.com](https://www.axios.com/2025/03/12/cvs-stores-pharmacies-drugs-retail#:~:text=struggling%20with%20oversized%20store%20footprints,Wolters%20Kluwer%20Health%2C%20told%20Axios)). 

• **Levers and KPIs:** Membership (Aetna) ticked up modestly; Rx 30-day scripts grew ~2% annually ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2024/CVS-HEALTH-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2023-RESULTS/default.aspx?os=dio____&ref=app#:~:text=expenses%20in%20the%20year%20ended,utilization%2C%20partially%20offset%20by%20a)). PBM (Caremark) same-store prescription volume was flat to up slightly. Management is refining pricing/rebate models (e.g. new “CVS CostVantage” for drug pricing). – 

**Investment Thesis:** CVS’s “payvider” model and scale drive secular growth. The company spans >9,000 retail pharmacies and 1,000 clinics, a PBM covering ~88M lives, and insurance (Medicare Advantage and commercial) serving ~37M members ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=CVS%20Health%20is%20a%20leading,model%20uses%20personalized%2C%20technology%20driven)). This integrated platform allows cross-selling and cost-savings (e.g. bundling drugs under PBM, steering patients to CVS clinics). Core secular drivers include an aging population (Medicare Advantage growth ~10%+ annually) and continued demand for value-based care. The pharmacy segment benefits from persistent demand for chronic and specialty medications (e.g. diabetes, obesity drugs).  CVS has high cash-flow margins (~3% operating margin historically) and generates ample free cash (~$6–7B now) despite recent pressures. Its dividend yield (~3.8% now) is one of the highest in the sector and it has raised the payout ~10% annually ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2023/CVS-HEALTH-REPORTS-STRONG-FOURTH-QUARTER-AND-FULL-YEAR-2022-RESULTS/default.aspx#:~:text=Announced%20a%2010,0%20billion%20share%20repurchase%20program)). Free cash flow supports moderate buybacks but CVS’s focus is debt reduction. Near-term catalysts include further MA star-rating gains, cost controls under new management, and growing utilization of in-store clinics and home health (post–Oak Street/Signify acquisitions). 

CVS addresses a massive U.S. health market (>$1.6T) with multiple revenue streams: pharmacy retail, PBM fees (Caremark), insurance premiums, and care services. These pillars each command large market share: e.g., ~25% of U.S. prescriptions and a top-3 PBM ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=CVS%20Health%20is%20a%20leading,model%20uses%20personalized%2C%20technology%20driven)). The company has rolled out initiatives (e.g. transparent pricing models, digital health tools) to lock in customers. With ~185 M annual customer encounters ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=,CVS%20Health%20President%20and%20CEO)), even small improvements in patient throughput or drug margin can meaningfully boost results. Over the cycle, CVS should leverage operating efficiency (store closures, IT investments) to expand EBITDA margin. Its balance sheet remains leveraged from Aetna, but consistent ~$12–13B OCF helps pare debt. Returns to shareholders (dividends + buybacks) residual to funding growth. Key catalysts: strong cost discipline driving FY25 EPS above mid-cycle, and any industry-wide easing of inflation. 

**Recent Developments:**  
• *Q1 2025 Results:* Reported May 1, 2025: Revenue +7% to $94.6B; EPS $1.41 vs $0.88 ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=First%20Quarter%20Financial%20Highlights)), beating estimates. Management raised FY adj EPS to $6.00–$6.20 ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=2025%20Full)).  
• *Profit Forecast:* Exited ACA individual market by 2026; announced 2025 forecast boost on lower medical costs ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-health-raises-annual-profit-forecast-as-turnaround-gathers-steam-4015961#:~:text=%28Reuters%29%20,series%20of%20challenges%20last%20year)) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=,CVS%20Health%20President%20and%20CEO)). Stock jumped on earnings (to ~$69.84) ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-health-raises-annual-profit-forecast-as-turnaround-gathers-steam-4015961#:~:text=CVS%20shares%20jumped%205,75%20to%20%246%20previously)).  
• *Retail Changes:* Testing compact “apothecary” stores; closing ~270 existing sites (Mar 2025) ([www.axios.com](https://www.axios.com/2025/03/12/cvs-stores-pharmacies-drugs-retail#:~:text=struggling%20with%20oversized%20store%20footprints,Wolters%20Kluwer%20Health%2C%20told%20Axios)). In early 2024 CVS also shuttered some Target-embedded pharmacies to cut costs ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-to-close-some-pharmacies-within-target-stores-3272878#:~:text=%28Reuters%29%20,several%20months%20of%20the%20year)).  
• *PBM and Pricing:* Aetna/Caremark expanded formulary coverage of GLP-1 weight-loss drugs to boost Rx volume ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=,1%20drugs)). The FTC filed suit (Sept 2024) targeting Caremark and other PBMs over alleged insulin rebate practices ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-sues-drug-gatekeepers-over-high-insulin-prices-2024-09-20/#:~:text=2024,to%20secure%20substantial%20rebates%20from)).  
• *Debt/Treasury:* In Dec 2024 CVS commenced tender offers to retire ~$2–3B of high-coupon debt (notes due 2025–2048) ([www.prnewswire.com](https://www.prnewswire.com/news-releases/cvs-health-corporation-announces-cash-tender-offers-for-certain-of-its-and-aetnas-outstanding-notes-302319696.html#:~:text=Health%27s%20outstanding%20indebtedness,subsequent%20to%20the%20date%20hereof)), funded by new note issuance.  

**Earnings & Growth Analysis:**  
CVS’s revenue grew briskly through 2023–Q1’25 (≈4–11% annually) despite headwinds. Key drivers are insurance premium growth and healthcare utilization in its Aetna (“Health Care Benefits”) segment, plus  footing from new Medicare Advantage enrollees and better medical cost control. Pharmacy & Retail (“Consumer Wellness”) is bolstered by continued prescription volume growth (chronic and specialty meds) and higher specialty-drug discounts. By contrast, Health Services (pharmacy services to nursing homes, benefits tech, etc.) has declined due to prior Omnicare exit and pandemic-related repricing. Gross margin was stable, but operating margin swung widely year-to-year due to one-time items (opioid litigation, Omnicare writedowns, star revenue adjustments). For FY2025, we project high-single-digit revenue growth driven by ~7% HCB and Pharmacy growth, offset by flattish services revenue. Operating leverage is strong: adjusted EBITDA margin should expand as loss-making exchange and non-core businesses wind down.   

Looking at EPS: GAAP EPS plunged in 2024 (to $3.66) vs. $6.47 in 2023 due to non-recurring charges and weaker Aetna results. We expect a material rebound in FY25 GAAP EPS (~+$0.80+ increase vs. 2024) from ongoing MA recovery and lower litigation costs, though some runway for higher SG&A (store/clinic buildouts). Adjusted EPS (which excludes amortization, litigation, etc.) should grow ~10–15%. In Q1, adjusted EBIT rose ~55% (to $4.579B), reflecting both volume growth and prior charges lapping; we expect the back half of 2025 to see normalized HCB claims and continued pharmacy margin, giving mid‐teens EPS growth from 2024.  

| **In Millions (except EPS)**         | **2021** | **2022** | **2023** | **2024** | **Q1’25**  |
|-------------------------------------|---------:|---------:|---------:|---------:|----------:|
| Total Revenues                      | 292.1    | 322.5    | 357.8    | 372.8    | 94.6      |
| Operating Income                    | 13.2     | 7.7      | 13.7     | 8.5      | 3.4       |
| GAAP Diluted EPS ($)                | 5.95     | 3.14     | 6.47     | 3.66     | 1.41      |

*Sources:* CVS Health press releases and SEC filings ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2023/CVS-HEALTH-REPORTS-STRONG-FOURTH-QUARTER-AND-FULL-YEAR-2022-RESULTS/default.aspx#:~:text=,term%20debt)) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx#:~:text=,4%2C227)) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2023/CVS-HEALTH-REPORTS-STRONG-FOURTH-QUARTER-AND-FULL-YEAR-2022-RESULTS/default.aspx#:~:text=Diluted%20earnings%20per%20share%20,01)) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx#:~:text=,1%20billion)).  

**Peer & Industry Analysis:** CVS straddles healthcare sectors.  By market cap it ranks below major insurers but above pure retailers: e.g. UnitedHealth (UNH, ~$500B) and Elevance (Anthem, ~$130B) dominate insurance; Walgreens (WBA, ~$30B) and Rite Aid (RITE, ~$8B) are pure drugstores; Cigna (CI, ~$67B) peers as integrated insurer. CVS’s peers have mixed growth: UNH/Elevance enjoy mid-single-digit EPS growth, higher P/Es (~18–20×) and high ~10%+ net margins; WBA/Rite have low-margin retail (<3% net) and trade ~10–15×. CVS sits near the value end of the “Managed Care/Pharmacy” spectrum (FY24 P/E ~18×; adjusted P/E ~12×). Its exposure to insurance adds growth potential yet also regulatory scrutiny. In a Value/Growth matrix, CVS is balanced – not a pure tech-like growth stock, but more stable than a grocery retailer, especially given its recurring-member revenues.  

**Financial Strength & Dividend:** CVS’s balance sheet is leveraged (long-term debt ~$59B, short-term ~$1.3B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=match%20at%20L216%20Total%20current,3%2C806))) vs. equity ~$77B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Total%20shareholders%E2%80%99%20equity%20%20,253%2C215)). Cash of ~$10.1B ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Cash%20and%20cash%20equivalents%20,28%2C934)) is healthy, and OCF (~$12–13B/year pre-2025) funds capex, dividends and debt paydown. Working capital is negative (~–$15.8B) by design (receivables & insurance payables exceed inventories) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=Cash%20and%20cash%20equivalents%20,28%2C934)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=match%20at%20L216%20Total%20current,3%2C806)). Debt/EBITDA is ~3–4×, and interest expense (~$785M/Q1) is rising modestly. We rate financial strength Medium: ample liquidity but substantial leverage. The dividend is well-covered; the quarterly payout has grown ~10% per year (67¢ vs 60.5¢ this time last year ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=The%20quarterly%20cash%20dividend%20declared,Company%E2%80%99s%20earnings%2C%20capital%20requirements%2C%20financial))), yielding ~3.8%. Share repurchases have been modest recently (CVS paused large buybacks after 2020), so share count should decline slowly if cash allows.  

**Management & Risks:** CEO David Joyner officially took over in late 2024 (succeeding Karen Lynch), while Brian Adams remains CFO. Management has improved guidance transparency and emphasizes the integrated model. Key risks: *Regulatory/legal:* FTC’s Sep 2024 lawsuit targets Caremark (CVS’s PBM) for alleged anti-competitive insulin rebates ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-sues-drug-gatekeepers-over-high-insulin-prices-2024-09-20/#:~:text=2024,to%20secure%20substantial%20rebates%20from)). The DOJ has also sued Aetna (CVS) over alleged Medicare Advantage kickbacks ([www.axios.com](https://www.axios.com/2025/05/01/medicare-advantage-plans-illegal-kickbacks#:~:text=The%20U,Court%20for%20the%20District%20of)), potentially constraining MA profits. *Policy:* Drug pricing and Medicare reforms could squeeze margins if aggressive. *Competitive:* Walmart, Amazon, and other disruptors are pushing same-day Rx and expanding retail health (exacerbating front-store pressures) ([www.ft.com](https://www.ft.com/content/a0fb7bee-a8f6-4e33-b07b-e9aa2f43edd7#:~:text=2024,day)) ([www.investing.com](https://www.investing.com/news/stock-market-news/cvs-to-close-some-pharmacies-within-target-stores-3272878#:~:text=U,weary%20consumers%20and%20intense%20competition)). *Macro:* Elevated healthcare cost trends (medical inflation, labor costs) remain a headwind (reflected in raised contingencies and conservative guide), as seen in recent forecast cuts. *Economic:* An economic slowdown could reduce discretionary spending in retail/pharmacy. *Leverage:* High debt means rising interest rates could pressure net income (interest expense was +11% YOY in 2024 ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx#:~:text=,compared%20to%20the%20prior%20year))). 

**Company Description:** CVS Health is a large U.S. healthcare “payvider” network. As of 3/31/2025 it operated ~9,000 pharmacies and 1,000+ clinics (MinuteClinic, etc.), a leading PBM (Caremark) with ~88 million plan members, and insurance products (Aetna) covering ~37 million beneficiaries (including Medicare Advantage) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=CVS%20Health%20is%20a%20leading,model%20uses%20personalized%2C%20technology%20driven)). Information technology and an integrated retail/pharmacy platform connect these segments; the strategy is to improve access and outcomes while lowering total cost. CVS’s offerings span prescription retail, mail order, specialty pharmacy, pharmacy benefit management, and value-based health plan services. 

**Valuation:** We value CVS primarily on a P/E basis against historical norms and peers. At our $72 target, the stock trades at ~14× 2025E GAAP EPS (mid-point of guidance) and ~11× adjusted EPS, in line with the company’s 5-year average internals and roughly the lower end of insurers’ P/E range. By comparison, UnitedHealth and Elevance trade at ~18–20× EPS, while Walgreens (~10–12×) has weaker growth. Our target is anchored to ~P/E 13–14× FY2025 (reflecting stabilized margins and moderate growth), and roughly 0.2× P/S (vs. 0.2–0.4× peers). If results exceed expectations (e.g., stronger MA pricing or synergies), multiple re-rating would follow; conversely, further cost overruns or regulatory fines would bear on valuation. The stock is at roughly fair value; upside hinges on sustained turnaround (improved HCB profits, pharmacy growth) beyond current forecasts, while downside risk centers on the identified regulatory and cost pressures.  

**Rating Definitions:** We assign ratings on a *12-month total-return* horizon. **BUY** denotes expected total return well above market benchmark on a risk-adjusted basis; **HOLD** means roughly in line with benchmark (or limited upside relative to known risks); **SELL** implies expected underperformance. (These are broad guidelines, not firm-specific recommendations.)  

**Methodology & Disclaimers:** Our analysis combines macro and industry outlooks with company-specific fundamentals. We assess market size/growth and CVS’s positioning (integration of retail-PBM-insurance), drive assumptions for revenue and margin, and evaluate cash flow/financial health. Valuation uses both comparable multiples and discounted cash flows, cross-checked with market trends. We consider management track record and key execution risks. This report is for informational purposes only and not investment advice. 

**Sources:** CVS Health – “First Quarter 2025 Results and Guidance” (press release, 2025-05-01) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=First%20Quarter%20Financial%20Highlights)) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FIRST-QUARTER-2025-RESULTS-AND-UPDATES-FULL-YEAR-2025-GUIDANCE/default.aspx#:~:text=2025%20Full)); CVS Health – “Fourth Quarter and Full-Year 2024 Results” (press release, 2025-02-12) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx#:~:text=,19)) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2025/CVS-HEALTH-CORPORATION-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2024-RESULTS/default.aspx#:~:text=Diluted%20earnings%20per%20share%20,42)); CVS Health – “Fourth Quarter and Full-Year 2023 Results” (press release, 2024-02-07) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2024/CVS-HEALTH-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2023-RESULTS/default.aspx?os=dio____&ref=app#:~:text=KEY%20FINANCIAL%20DATA)) ([investors.cvshealth.com](https://investors.cvshealth.com/investors/newsroom/press-release-details/2024/CVS-HEALTH-REPORTS-FOURTH-QUARTER-AND-FULL-YEAR-2023-RESULTS/default.aspx?os=dio____&ref=app#:~:text=,4%20billion)); CVS Health – “Full-Year 2022 Results” (press release, 2023-02-08) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2023/CVS-HEALTH-REPORTS-STRONG-FOURTH-QUARTER-AND-FULL-YEAR-2022-RESULTS/default.aspx#:~:text=,term%20debt)) ([investors.cvshealth.com](https://investors.cvshealth.com/news/news-details/2023/CVS-HEALTH-REPORTS-STRONG-FOURTH-QUARTER-AND-FULL-YEAR-2022-RESULTS/default.aspx#:~:text=Diluted%20earnings%20per%20share%20,01)); Tina Reed – *“CVS goes small in latest retrenchment move”* (Axios, 2025-03-12) ([www.axios.com](https://www.axios.com/2025/03/12/cvs-stores-pharmacies-drugs-retail#:~:text=Driving%20the%20news%3A%20CVS%20Health,selling%20greeting%20cards%20and%20cosmetics)) ([www.axios.com](https://www.axios.com/2025/03/12/cvs-stores-pharmacies-drugs-retail#:~:text=struggling%20with%20oversized%20store%20footprints,Wolters%20Kluwer%20Health%2C%20told%20Axios)); Reuters – *“US FTC sues drug ‘gatekeepers’ over high insulin prices”* (2024-09-20) ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/us-ftc-sues-drug-gatekeepers-over-high-insulin-prices-2024-09-20/#:~:text=2024,to%20secure%20substantial%20rebates%20from)); Sara Randazzo – *“DOJ alleges Medicare Advantage plans paid illegal kickbacks”* (Axios, 2025-05-01) ([www.axios.com](https://www.axios.com/2025/05/01/medicare-advantage-plans-illegal-kickbacks#:~:text=The%20U,Court%20for%20the%20District%20of)); MacroTrends – *“CVS Health: 52-Year Stock Price History”* (accessed 2025) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/stock-price-history#:~:text=2022.%20,below%20the%20current%20share%20price)) ([www.macrotrends.net](https://www.macrotrends.net/stocks/charts/CVS/cvs-health/stock-price-history#:~:text=Sector%20%20,Its%20offerings%20include)); CVS Health – Q1 2025 Form 10-Q (filed 2025-05-01) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=As%20of%20April%C2%A023%2C%202025%2C%20the,common%20stock%20issued%20and%20outstanding)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/64803/000006480325000013/cvs-20250331.htm#:~:text=The%20quarterly%20cash%20dividend%20declared,Company%E2%80%99s%20earnings%2C%20capital%20requirements%2C%20financial)).